New drug sorts out premature ejaculation

	Tweet

According the American Urological Association, premature ejaculation affects about 20% of males in the U.S. aged 18-59.

Premature ejaculation (PE) occurs before or soon after penetration; it often happens to men occasionally but can be a problem for many men and their partners if it happens regularly.

It is the most common male sexual dysfunction and is thought to be psychological but it can also be biological.

It has two classifications, primary premature ejaculation, where a man has experienced premature ejaculation throughout his sexually active life, and secondary premature ejaculation, which a man develops after have satisfying sex without ejaculatory problems.

Now a new drug, an antidepressant appears to treat the condition successfully and is apparently safe to use.

The antidepressant Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) and is the first treatment specifically designed for premature ejaculation and in two major clinical trials involving 2,600 men suffering from premature ejaculation, the treatment was effective and delayed orgasm.

Dr. Jon Pryor, of the University of Minnesota in Minneapolis who led the study, says Dapoxetine was effective and generally well tolerated and improved improved patients’ perceptions of control over ejaculation, and their satisfaction with sexual intercourse.

The men in the studies were given either a placebo or Dapoxetine which they took one to three hours before having sex.

The researchers say that after 12 weeks of treatment there was a three- to four-fold increase in the time to ejaculation; side effects of the drug included nausea, diarrhoea, headache and dizziness.

Last October, the U.S. Food and Drug Administration (FDA) refused to approve the drug and Johnson & Johnson’s Alza Corporation, the manufacturer, said it would continue to develop the treatment and would address questions raised by the FDA.

More men are affected by premature ejaculation than erectile dysfunction, the condition that made Pfizer’s impotence drug Viagra such a hit.

The research is published in The Lancet.

RELATED STORIES:
How do I masturbate?   Prevalence and Risk Factors of Sexual Dysfunction in Men and Women   Male Menopause: Holding Back the Years   A study confirms the importance of sexual fantasies in the experience of sexual desire   Study: Couples who delay having sex get benefits later   Women overestimate effectiveness of Pill, condoms   Epidemiology of chlamydial infection: are we losing ground?   HIV increases among women many powerless over sex   Understanding the process of homosexual identity formation among Asian and Pacific Islander youth   Infertile women may have more sexual problems   Does Psychological Treatment for Adult Sex Offenders Work?   Study finds sex a significant predictor of happiness among married seniors   Sex: The Stress Buster   Genes link puberty timing and body fat in women   Sexual Matters Don’t Sway Mothers on HPV Vaccine

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]